搜索结果


   CA4

靶点ID:TCMBANKGE004450


靶点别名:CAIV; Car4; RP17


靶点描述:carbonic anhydrase 4


染色体:17


染色体位置:17q23.1


靶点类型:protein-coding


HERB_ID:-


HGNC_Link:1375


OMIM_Link:114760


Ensembl_Link:ENSG00000167434


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN014187 seo-wenyujinacid B C2H6OS or HSCH2CH2OH C(CS)O
TCMBANKIN021519 Fraxinol fraxinol; 6-hydroxy-5,7-dimethoxy-2-chromenone; 486-28-2; 2H-1-Benzopyran-2-one, 6-hydroxy-5,7-dimethoxy-; 6-hydroxy-5,7-dimethoxy-chromen-2-one; 6-hydroxy-5,7-dimethoxychromen-2-one; 6-hydroxy-5,7-dimethoxy-coumarin C11H10O5 222.19 COC1=C(C(=C2C=CC(=O)OC2=C1)OC)O
TCMBANKIN048218 fraxetin ZINC00113309; NCGC00096046-01; AIDS224554; SCHEMBL43472; ST24045548; KBio3_002724; BSPBio_003224; SMR000112323; V1540; Coumarin, 7,8-dihydroxy-6-methoxy; AJ-11417; UNII-CD3GD44O3K; CD3GD44O3K; C09265; 7,8-Dihydroxy-6-methoxy-2H-chromen-2-one; Spectrum_001507; STOCK1N-06249; 7,8-dihydroxy-6-methoxy-2-chromenone; CTK8E5461; MCULE-2693568829; AC1NRV6E; InChI=1/C10H8O5/c1-14-6-4-5-2-3-7(11)15-10(5)9(13)8(6)12/h2-4,12-13H,1H; 7,8-Dihydroxy-6-methoxy-chromen-2-one; MFCD00006873; AKOS000277991; Spectrum4_001686; CHEBI:5169; 7,8-Dihydroxy-6-methoxy-2-benzopyrone; 574-84-5; N1765; KSC-11-207-12; 7,8-dihydroxy-6-methoxychromen-2-one; Fraxetin; 7,8-Dihydroxy-6-methoxycoumarin, 98%; CC-23048; SR-05000002449-1; NCGC00169075-01; BG01517128; 254916_ALDRICH; 7,8-Dihydroxy-6-methoxy-2H-chromen-2-one #; ZINC113309; I14-19210; SR-05000002449; ZB003792; ACon0_001071; AX8110148; Q-100662; EINECS 209-376-2; Spectrum3_001842; MLS002207123; AK114503; KBio2_007123; NCGC00096046-02; KBio2_004555; SpecPlus_000477; 7,8-dihydroxy-6-methoxy-chromen-2-one; ST024715; KBio2_001987; KBio1_001517; CCG-38759; NCGC00017270-03; Spectrum2_001639; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-6-methoxy-; ACon1_000442; SC-65962; AN-46013; BG00604311; Spectrum5_000332; Oprea1_735469; KBioSS_001987; MolPort-001-683-945; KBioGR_001952; 574F845; 7,8-dihydroxy-6-methoxy-coumarin; NCGC00169075-02; KUC106681N; SPECTRUM1504069; SPBio_001737; DB-050316; TR-020064; AC1Q4F2E; DTXSID00205992; NCGC00017270-05; CHEMBL54909; BDBM50206215; C-30832; DivK1c_006573; AIDS-224554; Fraxetin, analytical standard; FT-0632418; 4CN-1003; NCGC00017270-02; BRD-K76587808-001-03-8; MEGxp0_000506; NCGC00017270-01; TNP00177; HAVWRBANWNTOJX-UHFFFAOYSA-N; 7,8-Dihydroxy-6-methoxycoumarin; NCGC00017270-04; Coumarin, 7,8-dihydroxy-6-methoxy-; KB-249406 C10H8O5 208.168 c1(OC([H])([H])[H])c([H])c(C([H])=C([H])C(=O)O2)c2c(O[H])c1O[H]
TCMBANKIN057931 DMR CHEBI:30796; 02300_FLUKA; Malic acid, L(+)-; L(+)-Malic acid; C00497; InChI=1/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9; butanedioic acid, 2-hydroxy-; (R)-()-2-Hydroxysuccinic acid; (2R)-2-hydroxysuccinic acid; D-()-Malic acid; D-Hydroxybutanedioic acid; EINECS 211-262-2; (R)-malic acid; Malic acid D-(+)-form; 2-HYDROXY-SUCCINIC ACID; MLS000069520; (2R)-2-hydroxybutanedioic acid; 46940U_SUPELCO; SMR000058580; (+)-D-malic acid; Malic acid, D-; R-malic acid; D- malic acid C4H6O5 134.09 g/mol C(C(C(=O)O)O)C(=O)O
TCMBANKIN057960 glutathion glutathione C10H17N3O6S 307.33 g/mol C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N
TCMBANKIN059452 ethyl aldehyde C2H4O 44.05 g/mol CC=O
TCMBANKIN060111 17alpha-estradiol C18H24O2 272.4 g/mol CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O
TCMBANKIN061440 Phytodolor AIDS348374; 7-hydroxy-6,8-dimethoxychromen-2-one; NSC324637; ISOFRAXIDIN B814484K143; 7-hydroxy-6,8-dimethoxy-chromen-2-one; NSC 324637; 2H-1-Benzopyran-2-one, 7-hydroxy-6,8-dimethoxy-; Umbelliferone, 6,8-dimethoxy-; 7-Hydroxy-6,8-dimethoxy-2H-1-benzopyran-2-one; AIDS-348374; BRN 0202652; 7-hydroxy-6,8-dimethoxy-2-chromenone; 2H-1- Benzopyran-2-one, 7-hydroxy-6,8-dimethoxy-; 7-hydroxy-6,8-dimethoxy-coumarin; Isofraxidin; 486-21-5; 5-18-04-00332 (Beilstein Handbook Reference); Coumarin, 7-hydroxy-6,8-dimethoxy-; isofraxidin; 486I215; AC-8051; Q-100542; SCHEMBL3924718; 7-hydroxy-6,8-dimethoxychromen-2-one; HOEVRHHMDJKUMZ-UHFFFAOYSA-N; UNII-304915F056; NSC324637; V1549; 6,8-dimethoxy-7-hydroxycoumarin; ISOFRAXIDIN B814484K143; 7-hydroxy-6,8-dimethoxy-1-benzopyran-2-one; Isofraxidin, analytical standard; 7-hydroxy-6,8-dimethoxy-chromen-2-one; C17480; NSC 324637; 2H-1-Benzopyran-2-one,7-hydroxy-6,8-dimethoxy-; CTK8E5534; SC-17017; 2H-1-Benzopyran-2-one, 7-hydroxy-6,8-dimethoxy-; Umbelliferone, 6,8-dimethoxy-; 7-Hydroxy-6,8-dimethoxy-2H-1-benzopyran-2-one; CHEMBL451518; AC1NSX0O; Phytodolor; 6,8-dimethoxy-7-oxidanyl-chromen-2-one; FT-0688350; Ambotz486-21-5; TR-017709; A827571; NSC-324637; 6,8-Dimethoxyumbelliferone; AN-8405; DTXSID70197557; I14-19008; BRN 0202652; 7-Hydroxy-6,8-dimethoxycoumarin; LS-39687; FT-0698467; BG01525210; Isofraxidin; AKOS000278010; 486-21-5; 5-18-04-00332 (Beilstein Handbook Reference); MCULE-8927053707; ZINC1573299; 304915F056; Coumarin, 7-hydroxy-6,8-dimethoxy-; CHEBI:81121; W-2732; MolPort-000-882-100 C11H10O5 222.19 COC1=C(C(=C2C(=C1)C=CC(=O)O2)OC)O

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI002718 - - Finding phenotype
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI004059 - Abnormality of the eye Finding phenotype
TCMBANKDI006900 - Abnormality of head or neck Finding phenotype
TCMBANKDI007228 - - Finding phenotype
TCMBANKDI017965 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Finding phenotype
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI028908 Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases Abnormality of the eye Disease or Syndrome phenotype
TCMBANKDI032498 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease